Ascletis is an innovative R&D driven biotech listed on Hong Kong Stock Exchange (1672.HK). Ascletis is committed to developing and commercializing innovative drugs in the areas of NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS for unmet medical needs in China and globally. Led by a management team with deep expertise and a proven track record, Ascletis has developed into a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Gannex, a wholly-owned company of Ascletis, is fully dedicated to the R&D and commercialization of new drugs in the field of NASH. Gannex has three clinical stage drug candidates against three different targets – FASN, THR-beta and FXR, and three combination therapies.
最近 90 天内有 8 个信号。
该公司进入各个市场的顺序 — 从最早到最新
歌禮制药于ADA展示肥胖治疗管线
歌礼于ADA展示肥胖治疗产品管线
注册以查看完整信号动态
Ascletis Pharma Inc. 的国际扩张与竞争对手的对比情况
Ascletis Pharma Inc.你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Ascletis Pharma Inc.你 | 2 | 1 | -67% | 8 | 7 |
当前没有招聘
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
歌礼制药的ASC30皮下储库型制剂在3次月度给药后显示7.5%的显著减重，效果可持续4个月，有望成为季度维持疗法。
欧舒丽的ASC30皮下注射制剂在16周时实现7.5%体重减轻，最后一剂后维持4个月，显示每月治疗和每季维持疗法的潜力。
歌礼制药的ASC30皮下储库型制剂在3次月度给药后显示7.5%的显著减重，效果可持续4个月，有望成为季度维持疗法。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Ascletis Pharma Inc. 的业务、市场和增长信号的快速解答。
